Us Expanded Access Program For Transcon News Today

By Chris Wack Ascendis Pharma A/S said Monday that the U.S. Food & Drug Administration has found deficiencies in the companys new drug application for TransCon PTH, its candidate for the... | April 3, 2023

By Chris Wack Ascendis Pharma A/S shares were down 30% at $74.95 Monday after the company said the U.S. Food & Drug Administration found deficiencies in the companys new drug application... | April 3, 2023